Kornimate/medical-research-clean huggingface dataset:
a prospective evaluation of the filler for jaw contouring

Conditions: Dermal Fillers

Summary: the goal of this prospective study is to analyze volumetric changes in the lower face after hyaluronic acid filler injections over 90 days. the main question it aims to answer is: to quantify volume change of the lower face area over time after injection of filler * participants will receive hyaluronic acid filler injections (juvéderm volux xc) for contouring of the jawline. each patient will receive fda approved dosages of filler to the lower face region to treat facial contour or asymmetry, as per fda approved indications. * prior to injection patients will be imaged with 3-dimensional photogrammetry. subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging.


Eligibility criteria:
inclusion criteria: 1. age 22-55 2. patients interested in jaw contouring 3. participants must sign the informed consent form. exclusion criteria: 1prior filler for facial contouring 2) filler injection within the past 12 months or during duration of study 3) prior facial cosmetic surgery (ie. facelift) 4) prior facial trauma (ie. orbital fracture) 5) pregnant or breastfeeding 6) planned dental work within next 2 weeks 7) the following contraindications: patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies, gram-positive bacterial protein allergies and lidocaine allergies

Keywords: jaw hyaluronic acid ha filler hyaluronic acid filler filler cosmetic face dermal fillers chin
medication reconciliation in comparison to an extensive medication safety check

Conditions: Elderly; Adverse Drug Event

Summary: the purpose of this study is to determine wether an extensive medication safety check has a greater impact on the incidence of adverse drug events than medication reconciliation or no intervention.


Eligibility criteria:
inclusion criteria: * patient 65 years and older * written informed consent patient or the legal representative * existing medication therapy at hospitalization * admission to one of the project wards via emergency department (non elective) exclusion criteria: - patients included in the study previously

Keywords: elderly patients medication safety pharmaceutical care medication reconciliation
virtual reality hypnosis for chronic pain reduction

Conditions: Burns

Summary: we would like to determine how well hypnosis works when induced through virtual reality medium for patients who have suffered a major burn injury in the past two years and suffer from chronic pain. these patients are coming back to the outpatient burn and plastic clinic at harborview medical center for routine follow-up. we think that patients will find vr-hypnosis interesting, and it will help them relax and feel less pain.


Eligibility criteria:
inclusion criteria: * age 13 - 75 years * able to complete subjective evaluations of pain * english-speaking * able to communicate orally exclusion criteria: * age less than 13 years or greater than 75 years * incapable of indicating subjective evaluation of pain * non-english-speaking (virtual reality hypnosis only available in english) * demonstrating delirium, psychosis, or organic brain disorder * unable to communicate verbally * significant developmental disability * extreme susceptibility to motion sickness * significant head/or neck injury * pregnant women
what is the incidence of an immune disorder in children with invasive pneumococcal disease (ipd)?

Conditions: Invasive Pneumococcal Disease, Recurrent Isolated, 1; Invasive Pneumococcal Disease, Recurrent Isolated, 2; Invasive Pneumococcal Disease, Protection Against; Primary Immunodeficiency

Summary: this is a multicentre prospective audit to determine the incidence of immunodeficiency in children with ipd. aims and/or research question of the project 1. to determine the incidence of primary immunodeficiency in children \>2 years who present with ipd 2. to determine the types of immunodeficiency associated with ipd in children


Eligibility criteria:
inclusion criteria: * children aged 0 to 18 years admitted to one of the six centres with ipd. exclusion criteria: * children who do not fulfil the age criteria for immunological evaluation at that particular site e.g. aged \<2 years at royal children's hospital. * children with a known underlying condition predisposing to ipd i.e. nephrotic syndrome.

Keywords: streptococcus pneumoniae invasive pneumococcal disease primary immunodeficiency
shear wave elastography new ultrasound approach for the erectile dysfunction

Conditions: Erectile Dysfunction; Penile Diseases

Summary: the study proposes the use of a new non-invasive ultrasound method for the diagnosis of erectile dysfunction. in particular, the shear wave elastosonosgraphy of the corpora cavernosa will be used. this last method quantitatively measures the rigidity of the analyzed tissues.

erectile function is a complex mechanism in which the elasticity of the tissues that make up the corpora cavernosa is fundamental. indeed, anatomopathological studies have shown that in patients with erectile dysfunction the elastic fibers are replaced by inextensible collagen. the aim of the study is the correlation between penile stiffness measured with this new non-invasive diagnostic method - elastosonography of the corpora cavernosa - and the correlation with validated questionnaires. the international index of erectile function (iief5) short form and the erectile hardness score (ehs) will be used.

Eligibility criteria:
inclusion criteria: male who came attended our general andrology clinic between january 2019 to january 2020. exclusion criteria: 1. with: age \>80 years or \<18 years. , 2 2. diabetes, 3. spinal trauma, 4. treatment with continuous pde5i, 5. ischemic heart disease for less than 6 months, 6. pelvic surgery for within less than 1 year, 7. hypotestosteronemia (\<8 nmol/l), 8. la peyronie's disease. 9. penile trauma.

Keywords: erectile dysfunction elastosonography penile diseases international index of erectile function erectile hardness score
melatonin for patients with chronic low back pain

Conditions: Chronic Low-back Pain (cLBP)

Summary: low back pain is one of the conditions causing more disability worldwide. the use of pain medications is substantial in patients with chronic lbp. but the efficacy of commonly used analgesics is modest. more than half of patients with chronic lbp also has sleep problems. in recent years, some preliminary studies have shown a promising effect of melatonin for the treatment of pain. the objective of this study is to investigate the efficacy of melatonin, relative to placebo, in patients with chronic lbp.


Eligibility criteria:
inclusion criteria: * age 18-65 * understand and write dutch * lbp for 3 months or longer * lbp must be present on 'most days' or 'every day' within the past 3 months * lbp must limit life or work activities on 'some days', 'most days', or 'every day' within the past 3 months * average lbp intensity of ≥4 on a 0-10 nrs in the past 7 days exclusion criteria: * lbp resulting from a specific cause such as malignancy, fracture, lumbar radiculopathy and spinal stenosis * radiating pain into the leg that goes further (down) than the knee * inflammatory/autoimmune arthritis * severe physical or psychiatric co-morbidities * contraindications to melatonin

Keywords: chronic low back pain melatonin
mrd-guided adjuvant tislelizumab and chemotherapy in resected stage iia-iiib nsclc

Conditions: NSCLC

Summary: seagull is a phase ⅱ study designed to investigate the efficacy and safety of mrd-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable nsclc

in the phase ii trial, the efficacy and safety of mrd-guided adjuvant tislelizumab and chemotherapy will be compared with that of standard adjuvant tislelizumab and chemotherapy in patients with resectable nsclc.

Eligibility criteria:
inclusion criteria: 1. patient with age ≥ 18 years old, gender is not limited. 2. histologically confirmed primary nsclc, postoperative stage is iia, iib, iiia or t3n2iiib. 3. receiving complete resection 4. paraffin-embedded sections (10-15 pieces) or fresh frozen tissue are required. 5. ecog score of 0 or 1. 6. females of childbearing age should take appropriate contraceptive measures from screening to 3 months after discontinuation of study treatment and should not breastfeed. the pregnancy test was negative before starting dosing. 7. male patients should use barrier contraception from screening to 3 months after discontinuation of study treatment. 8. the subjects themselves participated voluntarily and signed the informed consent in writing. exclusion criteria: 1. the patient has received immune checkpoint inhibitors such as anti-pd-1, pd-l1 or ctla-4, other immunotherapy or systemic immune modulators (including but not limited to interferon, il-2 and tnf etc). 2. histopathology with small cell or large cell endocrine tumor component. 3. harboring egfr sensitizing mutation or alk gene translocation 4. history of other malignant tumors, except for non-melanoma skin cancer, carcinoma in situ or other solid tumors that have been effectively treated, and no evidence of any disease for \>5 years after the last treatment. 5. at the start of the study treatment, there are residual toxicities of the previous treatment that are greater than ctcae 1 and have not been alleviated, except for alopecia and grade 2 neurotoxicity caused by previous chemotherapy. 6. any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, active bleeding, active infection including hepatitis b, c, hiv, etc., which the investigator considers unsuitable to participate in the study or affect the trial program compliance. 7. history of ild, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease 8. insufficient bone marrow reserve or organ function. 9. history of hypersensitivity reactions to any active or inactive ingredient of tislelizumab or to drugs that are chemically similar to tislelizumab or in the same class of tislelizumab. 10. patients who, in the judgment of the investigator, may not comply with the procedures and requirements of the study. 11. patients who, in the investigator's judgment, have any condition that compromises patient safety or interferes with the evaluation of the study.

Keywords: ctdna-mrd
68ga-psma-11 pet in patients with prostate cancer

Conditions: Prostate Cancer; Prostate Adenocarcinoma

Summary: patients will receive a single dose of 68ga-psma-11 and undergo a pet/ct or pet/mri imaging study.

this is a prospective, phase iii, single-center, open-label to provide extended access in patients with biochemically recurrent prostate cancer. approximately 100 patients are planned for enrollment in this study. patients will receive a single dose of 68ga-psma-11 and undergo a pet/ct or pet/mri imaging study. the intervention is a pet scan with the radiolabelled prostate-specific membrane antifen (psma) ligand, 68ga-psma-11. the pet may be combined with a ct scan as a pet/ct or an mri scan as pet/mri. 68ga-psma-11 pet/ct will be acquired using a modern digital ge pet/ct scanner or a modern digital pet / mri scanner. aes will be collected during injection and uptake phase (45-120 min posts infusion) of ga-68 psma-11 pet/ct scan. all safety events will be recorded up to 120 min post injection. men with pathologically proven prostate adenocarcinoma, high risk cancer at diagnosis, evidence of biochemical recurrence, or known metastatic disease planned to start and change systemic therapy regimen. one intravenous catheter will be placed for radiopharmaceutical administration. patients will be injected with 100 mbq (3mci)-300 mbq( 7mci) of 68ga-psma-11 via this catheter.

Eligibility criteria:
inclusion criteria: * histopathologically proven prostate adenocarcinoma * age ≥ 18 years * patients already diagnosed with prostate cancer: primary staging: intermediate and high-risk patients per nccn guidelines * biochemical recurrence: rising psa after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy): a. post radical prostatectomy (rp) - aua recommendation i. psa greater than or equal to 0.2 ng/ml measured more than 6-13 weeks after rp and confirmed by a second determination of a psa level of \>0.2 ng/ml b. post-radiation therapy - astro-phoenix consensus definition i. nadir + greater than or equal to 2 ng/ml rise in psa * ability to understand a written informed consent document, and the willingness to sign it. exclusion criteria: * unable to lie flat, still or tolerate a pet/ct scan, or any other condition that would preclude pet/ct imaging. * patients with any medical condition or circumstance that the investigator believes may compromise the data collection or lead to a failure to fulfil the study requirements. * patients with known hypersensitivity to the active substance or to any of the excipients of the investigational product.

Keywords: newly diagnosed
the prevalence of family-unit helicobacter pylori infection in jiangsu

Conditions: Helicobacter Pylori Infection

Summary: to assess family-unit helicobacter pylori infection rates and antimicrobial resistance rates in jiangsu,china

the study is a sample survey of the community population in cities of jiangsu where the centers are located.the helicobacter pylori infection and drug-resistant gene mutations are detected by real-time pcr performed on the stools of subjects.

Eligibility criteria:
inclusion criteria: 1. community population 2. fecal samples can be obtained, and the sample volume meets the requirements of the collection tube instructions 3. only one person per family can be selected 4. voluntarily participated in this study and signed an informed consent form exclusion criteria: 1. the collector does not cooperate or has poor compliance; 2. adequate and qualified fecal samples could not be obtained; 3. stool samples were collected during diarrhea or constipation; 4. antibiotics, bismuth preparations, proton pump inhibitors and other hp sensitive drugs have been used within one month.

Keywords: resistance mutation fecal drug resistance gene detection
helping moms to be healthy after baby

Conditions: Weight Loss; Diet Modification; Obesity

Summary: low-income and minority women are at increased risk for postpartum weight retention (i.e. retaining weight after pregnancy) and consequent persistent obesity. women who are obese pre-pregnancy are 3-5 times more likely to gain weight, rather than lose weight, in the postpartum period than non-obese women. aims for this pilot study are listed below: aim 1: to evaluate the feasibility and acceptability of a multi-component novel weight loss intervention delivered in a wic setting to a population of low-income, predominantly racial/ethnic minority, obese, postpartum women. aim 2: to evaluate differences in weight change, diet, physical activity, self-efficacy, readiness to change, motivations to eat between intervention and control participants to determine preliminary intervention efficacy over a 12-week period.

low-income and minority women are at increased risk for postpartum weight retention (i.e. retaining weight after pregnancy) and consequent persistent obesity. women who are obese pre-pregnancy are 3-5 times more likely to gain weight, rather than lose weight, in the postpartum period than non-obese women. obesity science supports that weight loss interventions should be multi-component with regular points of contact. building upon this, we have designed a multi-component intervention that considers the demands on women in the postpartum period and utilizes technology for both provider decision support and for virtual contact with participants. the intervention will address diet, physical activity, and social support through the use of in-person meetings with wic staff, text messaging, phone coaching, self-monitoring, and facebook.

Eligibility criteria:
inclusion criteria: * adult woman (≥18 and \<50 years old). * enrolled in wic or with an infant enrolled in wic. * 3-12 months postpartum. * a pre-pregnancy bmi of 25 - 40 kg/m2 (based on self-reported height and weight prior to pregnancy). * postpartum body mass index between 25 and 50 kg/m2. * english- and/or spanish-speaking. * owns a mobile phone with texting functionality in order to receive texts during the trial. exclusion criteria: * health conditions impacting weight or ability to participate in a weight loss trial. * pregnancy or planned pregnancy in next 5 months. * any health problems or undergoing any treatments that might interfere with what participant eats or her ability to exercise. * medical provider recommendation to avoid exercise. * plans to be in a different geographic area within the next 5 months. * plans to stop coming to aurora wic in the next 5 months. * unable to give informed consent. * not able to read and understand english or spanish at an 8th grade level. * not willing to create a facebook account if they do not already have one. * asked to follow-up in \< 3 months at most recent wic visit.
testing of a new computer screen for patients with persistent concussion symptoms (pcs).

Conditions: Post-Concussion Symptoms

Summary: this study will examine whether a newly designed monitor for computers is better tolerated by concussed patients than the standard computer monitor. the information gathered from this study will contribute to the understanding of the persisting concussion symptoms including computer screen intolerance and photosensitivity, with the aim of helping those with concussions.

the study will involve completing a reading task on the standard computer monitor and the newly designed computer monitor. first, participants will be asked to rate their pre-test symptoms using a scat-iii symptom checklist. then they will read a short story and watch moving images on one of the devices (standard computer monitor or the newly designed computer monitor) for 30 minutes or until persisting concussion symptoms of moderate severity arise. then, they will be asked to rate their post-test clinical symptoms using a scat-iii symptom checklist. on a second visit, 7 to 10 days later, they will do the same activity on the other device. each visit will take 60 minutes. the study will involve 100 patients with a history of concussion and computer screen intolerance.

Eligibility criteria:
inclusion criteria: * diagnosis of persisting concussion symptoms (1 month to 5 year since concussion) * must speak english * must provide written consent * no alcohol/recreational drug use within 24 hours of intervention * no other neurological, psychiatric or ocular conditions exclusion criteria: * no diagnosis of persisting concussion symptoms * under the age of 18, over the age of 65 * other neurological/psychiatric or ocular conditions * alcohol or recreational drug use within 24 hours of intervention
evaluation of an educational program in the prevention of the driving risks in patients with neurocognitive disorders : accompagne

Conditions: Driving Habits Patients; Cognitive Impairment

Summary: accompagne study proposes to evaluate an educational program for the patient / caregiver dyad, intended to accompany the patient towards the implementation of self-regulation strategies in the driving activity. the program, based on group workshops with the presence of the patient and the caregiver, is led by an interdisciplinary team. it follows all the intervention recommendations described in the literature: to make the patient a decision-maker, to allow advanced planning of discussions between the family member and the caregiver, to give information on the consequences of tncs and sensory disorders. this program provides psychological support in the management of the problems and the mourning of a future cessation of the driving activity, an awareness of the risky and avoidable situations, information on alternative solutions and available resources in the event of reduced driving. the program is created to support the implementation of self-regulation strategies for safe driving and a gradual reduction of driving activity. this study may be included in measure 5 of the neuro-degenerative diseases plan (pmnd) 2014-2019. this plan recommends to strengthen the self-management of patients and their relatives in the disease.


Eligibility criteria:
inclusion criteria: * aged between 50 and 95 years-old * hold a driving license, * drive at least twice a week, * to have given free and informed consent, * present a diagnosis of major or minor cns according to dsm v, whose clinically probable or definite etiology is alzheimer's or related or vascular disease, * have a result in the mini mental state examination (mmse) greater than 18, * have the ability to speak orally enough or write enough to perform clinical evaluations and workshops, be accompanied by a family member present at least 4 hours a week. criteria for inclusion of carers: * to be a caregiver helping the patient for activities of daily living, * to have given their free and informed consent, * have the ability to speak orally and write enough to perform clinical assessments. exclusion criteria: * have a major psychiatric history, history of alcoholism, anti-depressant * have sensory problems preventing participation in workshops, * be affected by any debilitating pathology compromising the health of the patient in the short and medium term, * be unable to express consent. criteria for non-inclusion of caregivers: have sensory disturbances preventing participation in workshops. recruited patients and caregivers should have been informed and signed a consent.

Keywords: driving habits cognitive impairment prevention educational intervention
anatomical and perioperative predisposing factor for limb occlusion of incraft infrarenal endograft (limit study)

Conditions: Aneurysm Abdominal

Summary: the aim was to determine, within the patient enrolled in three controlled prospective studies, innovation, inspiration and insight (sponsor: cordis, a cardinal health company) studies which are preoperative and postoperative anatomical risk factors associated to limb occlusion. in the three studies the total number of enrolled patients was 400, of whom 134 enrolled in the us


Eligibility criteria:
inclusion criteria: * patients with abdominal aortic aneurysm, who have been treated with the incraft® grafting system (aaa stent-graft system). * all cases treated with incraft who were enrolled in three controlled prospective studies, innovation, inspiration and insight (sponsor: cordis, a cardinal health company) exclusion criteria: * no exclusion criteria

Keywords: abdominal aortic aneurysm